Mechanism — precursor vs direct
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in every major energy-production pathway in the cell — sirtuin activation, PARP-mediated DNA repair, oxidative phosphorylation. NAD+ levels decline ~50% by age 60 across most tissues, which is the mechanistic root of much age-related decline. The supplementation question: do you give the precursor (NMN, which converts to NAD+ in two enzymatic steps) or the molecule itself (NAD+, which has poor oral bioavailability)? NMN passes through the gut, enters cells via the Slc12a8 transporter (recently identified by Imai's lab), and gets converted to NAD+ by NMNAT enzymes. Direct NAD+ doesn't survive oral dosing intact — gut bacteria hydrolyze it to nicotinamide — so it has to be infused, injected, or absorbed sublingually.
- NMN: Oral precursor → NAD+ via NMNAT enzymes; ~1-step conversion in cells
- NAD+ direct: IV or sublingual delivery; bypasses precursor conversion; not orally bioavailable
- Why precursors exist: NAD+ direct can't survive the gut — NMN/NR are the workaround
Evidence — what published trials show
NMN: Yoshino et al. (2021 Science) showed 250 mg/day NMN over 10 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women. Liao et al. (2021 J Int Soc Sports Nutr) showed 600 mg/day NMN improved aerobic capacity in trained runners. Multiple safety + biomarker trials show NMN raises blood NAD+ levels in a dose-dependent manner (300 → 600 → 900 mg). Direct NAD+: clinical data is much thinner. Compromised NAD+ has been studied for addiction recovery, post-COVID fatigue, and Parkinson's, with mixed results — most studies are small (n<50) and open-label. The biggest NAD+ IV trial (Birkmayer protocol for addiction) ran in the 1960s-70s and doesn't meet modern RCT standards. Bottom line: NMN has the better evidence base for chronic dosing; NAD+ IV is mostly clinical wisdom + small studies.
- NMN — Yoshino 2021: 250 mg/day, 10 wks: improved muscle insulin sensitivity in prediabetic women
- NMN — Liao 2021: 600 mg/day: improved VO2 max + aerobic capacity in trained runners
- NAD+ IV: Limited modern RCT data; mostly small open-label trials + clinical practice
Dosing — daily oral vs periodic IV
NMN typical dose: 250-1000 mg/day oral, taken in the morning. Most published protocols use 300-500 mg/day; Sinclair himself runs 1 g daily based on personal/team observations. NMN is dose-responsive — blood NAD+ scales with dose up to ~1 g/day, then plateaus. NAD+ IV: typical clinical protocols infuse 500-1500 mg over 2-4 hours, dosed 1-3× per week during an active protocol (e.g., burnout recovery, addiction treatment, post-illness rehab). Sublingual NAD+ lozenges run 25-100 mg per lozenge with variable bioavailability (~20-40% absorbed). NR (nicotinamide riboside, the competing precursor) follows the same dosing pattern as NMN at 300-600 mg/day.
- NMN typical: 250-1000 mg/day oral, morning; dose-responsive up to ~1 g
- NAD+ IV clinical: 500-1500 mg over 2-4 hr, 1-3× per week during an active protocol
- Sublingual NAD+: 25-100 mg/lozenge; variable bioavailability (~20-40%)
Safety — both clean, NAD+ IV has procedure risk
NMN: extremely clean safety profile in published human trials. No serious adverse events at doses up to 1.2 g/day. Mild flushing in some users at 600+ mg (similar to niacin reaction). Long-term safety is supported by mouse data + 4+ years of widespread human use without significant signals. NAD+ IV: drug itself is safe, but the IV administration introduces procedure risks — infiltration, infection at injection site, very rare anaphylaxis. Infusions must be slow (>2 hours) because rapid push causes a chest pressure + flushing response (a known reaction, not dangerous but uncomfortable). Sublingual NAD+ is essentially side-effect free at typical doses. NR has a nearly identical profile to NMN — both raise NAD+ via similar pathways with comparable tolerability.
- NMN: Clean safety profile in trials; mild flushing >600 mg in some users
- NAD+ IV: Drug safe; IV procedure risks (infection, infiltration, slow-infusion required)
- Sublingual NAD+: Essentially side-effect free at typical doses
Cost — order of magnitude apart
NMN: high-quality bulk powder runs $0.40-1.00/g; capsulated retail (Tru Niagen, Renue by Science, ProHealth) runs $1.50-3.00/g. A 500 mg/day protocol costs $25-50/month from a reputable supplier. NAD+ IV at longevity clinics: $200-500 per session for 500-1500 mg. A typical "NAD+ boost" protocol (3 sessions/week for 2-4 weeks) totals $2,000-6,000. Sublingual NAD+ retail: $40-80/month at typical 25 mg/day. NR retail is roughly NMN-equivalent — $30-60/month for 300-600 mg/day. For chronic daily NAD+ support, NMN is the cost-effective default; NAD+ IV is for situational use when you need rapid restoration of NAD+ levels (severe burnout, post-illness, addiction recovery contexts).
- NMN powder: $0.40-1.00/g bulk; ~$25-50/month at 500 mg/day
- NAD+ IV: $200-500/session; protocol cost $2,000-6,000 for 8-12 sessions
- Sublingual NAD+: $40-80/month at 25 mg/day; convenience without IV infrastructure
Who chooses which
For chronic daily longevity support, NMN is the clear winner — published efficacy, low cost, easy oral dosing. For acute restoration of NAD+ (severe burnout, post-chemo fatigue, addiction recovery, intense athletic recovery), IV NAD+ has a real role despite the cost — the rapid peak NAD+ tissue levels can produce subjective effects that oral precursors can't match. Sublingual NAD+ is a reasonable middle ground for users who want some direct NAD+ delivery without IV infrastructure. NR vs NMN is largely a wash — same mechanism, similar dose-response — pick whichever your preferred supplier carries cheapest. Common longevity stack: NMN 500 mg morning + resveratrol or pterostilbene (to support sirtuin activation) + occasional IV NAD+ for athletic recovery or burnout windows.
